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Abstract Polyhalogenated benzo- and naphthoquinones were
found to be potent inhibitors of pure ureases from Bacillus pas-
teurii and Canavalia ensiformis. They also inhibited ureases in
whole cells of Helicobacter pylori, Klebsiella oxytoca and Pro-
teus mirabilis. Inhibition was non-competitive with Ki values in
the micromolar range or below. Inhibition was irreversible as
shown by equilibrium dialysis. Inhibitory power decreased con-
siderably when halogens were replaced by ^OH, ^CN, alkoxy
or alkyl groups.
& 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Ureases (urea amidohydrolases: E.C. 3.5.1.5) are multi-sub-
unit, nickel-containing enzymes that catalyze the hydrolysis of
urea to carbon dioxide and ammonia.
Bacterial ureases have been shown to be important viru-
lence factors in the pathogenesis of many diseases in humans
and animals [1,2]. The ammonia generated may severely dis-
turb metabolic functions in a large number of animal tissues
and organs [3,4]. Ammonia is involved in the formation of
infection stones in the urinary tract, which cause signi¢cant
health problems and damage [1,2,5]. Urease is also indispens-
able for colonization of human gastric mucosa by Helico-
bacter pylori. The ammonia produced has been shown to be
toxic for various gastric cell lines [2]. Furthermore, urease
activity was proposed to damage the gastric epithelium via
its interaction with the immune system by stimulating an oxi-
dative burst in human neutrophils [6]. H2O2 generated in this
oxidative burst probably reacts with ammonia and chloride to
yield the toxic monochloramine [7,8]. Finally, the ammonia
may reach the serum and contribute to symptoms of hepatic
encephalopathy in patients su¡ering from cirrhosis [9]. On site
ammonia itself inhibits lymphokine release [10] and the fourth
component of complement [11], thus lowering the cell-medi-
ated immune response and host defence mechanisms. The
consequences are acute in£ammation and epithelial cell ne-
crosis.
Apart from ammonia, the carbon dioxide generated by urea
hydrolysis may play a signi¢cant role for survival of H. pylori
in the gastric mucosa. Kuwahara et al. [12] could show that
this CO2 rapidly neutralizes peroxynitrite (ONOO3), which is
produced by the host, and which e⁄ciently kills H. pylori.
They demonstrated that a raise in local CO2 concentration
signi¢cantly enhanced the survival rate of the bacteria.
Therefore, strategies based on inhibition of urease are con-
sidered as treatment for infections caused by urease-producing
bacteria. The discovery of urease inhibitors has mainly relied
upon random screening of thousands of chemical compounds.
However, after determination of X-ray structures of native
and inhibited ureases a more directed search for inhibitors
has started (reviewed in [13]).
So far urease inhibitors can be divided into six major classes
based on their chemical structure [13] : hydroxamic acid de-
rivatives, phosphorodiamidates (PPD), imidazole derivatives,
phosphazenes, Ecabet sodium and N-substituted hydroxy-
ureas [14]. Several compounds (mainly acet-hydroxamic acid
and the PPD derivative £urofamide) have proved to be e¡ec-
tive in vivo, reducing, e.g., urethral catheter encrustation by
Proteus mirabilis [15], Ureaplasma infection in animals [16,17]
or Helicobacter-induced gastritis in Mongolian gerbils [18].
These studies indicate that urease inhibitors have the potential
to replace, e.g., the current treatment for peptic ulcer based on
the combination of an acid pump inhibitor and two antibiot-
ics [19], which is expensive and prone to development of anti-
biotic resistances.
We here report inhibition of various ureases by novel
classes of potent inhibitors ^ halogenated benzo- and naph-
thoquinones.
2. Materials and methods
2.1. Enzymes and chemicals
Ureases from Bacillus pasteurii and jack bean (Canavalia ensifor-
mis), and chloranilic acid were from Sigma (cat. no. U7127, U4002,
C-8136, respectively); tetra£uoro-p-benzoquinone (p-£uoranil, 10,435-
3), tetrachloro-o-benzoquinone (o-chloranil, T660-1), 2,3-dichloro-5,6-
dicyano-p-benzoquinone (D6,040-0), tetrachlorocatechol (T690-3)
from Aldrich; tetrachloro-p-benzoquinone (p-chloranil, 802361), tet-
rabromo-p-benzoquinone (p-bromanil, 820180), p-naphthoquinone
(806215) from Merck; 2,3-dichloro-p-naphthoquinone (35990) from
Fluka; p-benzoquinone, o-naphthoquinone, 2-methyl-6-methoxy-p-
benzoquinone were gifts from K. Dettner (Department of Animal
Ecology, University of Bayreuth). Dibromo-diiodo-p-benzoquinone
(probably a mixture of isomers) and tetraiodo-p-benzoquinone (ioda-
nil) were prepared and puri¢ed as described in [20]. The structural
formulas of these compounds are given in Fig. 1, and the correspond-
ing names in Table 1.
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2.2. Bacterial strains and their cultivation
Klebsiella oxytoca M5al (from R.H. Burris, Madison, WI, USA)
and P. mirabilis DSM30115 were grown in 20 ml minimal medium
[21] with 1% glucose and 5 mM urea as sole C and N sources (urea
stock solution 1 M, ¢lter sterilized); H. pylori strain Hp151 (from
T. Jahns, Saarbru«cken, Germany) in 100 ml brucella broth pH 7.0
(Difco, Detroit, MI, USA) with 2% fetal calf serum (Serva, Heidel-
berg, Germany) and 10 mg vancomycin (Sigma Aldrich, Deisenhofen,
Germany) under microaerobic conditions (85% N2, 10% CO2, 5% O2).
All cultivations were carried out at 37‡C.
2.3. Assay conditions
Bacteria pelleted from liquid cultures were washed 3U with 10 mM
potassium phosphate bu¡er (pH 7.0) and used in whole cell assays.
Urease activity was routinely determined as ammonia formation [22]
in a test mixture containing in a ¢nal volume of 0.8 ml: urea (0.25 M,
if not indicated otherwise), potassium phosphate (25 mM pH 7.0) and
variable amounts (5^50 Wl) of urease or bacterial cells, and inhibitors
as indicated. Inhibitors were dissolved in tert.-butyl-methyl ether
(stock solutions of 0.01^10 g l31, the solvent proved non-inhibitory
up to a 10% concentration.), pure ureases in 10 mM potassium phos-
phate pH 7.0. Protein content was determined by the microbiuret
method [23].
2.4. Reversibility tests
Reversibility of binding was tested by equilibrium dialysis. 0.25 ml
of urease solution (1 g l31) was mixed with di¡erent amounts of
inhibitors, left for 30 min at room temperature, placed into a dialysis
tube (Visking, molecular weight cut-o¡ 14 000, diameter 7 mm), and
dialyzed for up to 22 h against ¢ve changes of 100 ml 10 mM potas-
sium phosphate pH 7.0 (20‡C). Activity tests were routinely run at 0,
5 and 22 h.
3. Results
3.1. Inhibitory powers
As shown in Table 1 the Ki values for inhibition of pure
ureases decrease about 50-fold with halogenation of benzoqui-
none. Other substituents did not have the same or even ad-
verse e¡ects. The nature of the halogens seemed of less im-
portance. A calculation for the plant urease showed that at
the concentration employed (0.046 WM, molecular weight 273
kDa) [13] inactivation took place at an almost stoichiometric
2:1 ratio of some anils to urease, indicating a speci¢c site-
directed reaction. Inhibition always proved to be non-compet-
itive. For a rough calculation of the Ki values the formula for
pure non-competitiveness (Ki = [I]/(Vmax/v31), [I] = inhibitor
concentration) was considered su⁄cient.
Naphthoquinones were less e¡ective. Tetrachlorocatechol
had no e¡ect.
When testing whole cells, passage of the inhibitors across
the membrane had to be taken into account. Generally cells
and inhibitors had to pre-incubated to obtain stable values.
Pre-run experiments showed an incubation time of 2 h for all
inhibitors and cells to be su⁄cient. (Table 2.)
3.2. Reversibility of binding
Reversibility of binding is conveniently studied by equilib-
rium dialysis. Since successful dialysis depends on solubility of
the inhibitor in the dialysis bu¡er, relevant data had to be
collected or produced. A literature search yielded no data
for £uoranil or the naphthoquinones, and ‘insoluble in water’
for chloranil, bromanil and iodanil [20,24,25]. Our own ex-
periments (data not shown) showed a solubility of approxi-
mately 0.5 mM for £uoranil and 0.05 mM for chloranil in the
dialysis bu¡er. Both values by far exceed the solubility re-
quired for dialysis experiments by more than 10-fold. Fig. 2
shows the equilibrium dialysis data for £uoranil. As can be
seen, inhibition of the urease is not relieved even after 22 h of
dialysis. Similar data were obtained for chloranil (not shown).
These data strongly suggest irreversible binding of halogen-
ated benzoquinones to ureases.
4. Discussion
The results presented here demonstrate that halogenated
quinones are potent, irreversible inhibitors of several bacterial
and plant ureases. Other substituents tested (^OH, ^CN,
^OCH3, ^CH3) did not increase or rather decreased the inhib-
Fig. 1. Structural formulas for the quinones used in this study.
Table 1
Inhibition constants (Ki in mM) of quinones for pure ureases. Roman numerals in the brackets correspond to the structural formulas in Fig. 1
Inhibitor B. pasteurii urease C. ensiformis urease
p-Benzoquinone (I) 80 10
p-Fluoranil (II) 0.1 0.1
p-Chloranil (III) 0.2 0.2
o-Chloranil (IV) 4.8 3.5
p-Bromanil (V) 0.15 0.3
p-Iodanil (VI) 1.0 0.1
Di-Br,di-I-benzoquinone (VII) 0.2 0.1
Chloranilic acid (VIII) s 1000 100
2-CH3,-6-OCH3-benzoquinone (IX) 200 120
2,3-Cl,-5,6-CN-benzoquinone (X) 600 70
o-Naphthoquinone (XI) 70 5
p-Naphthoquinone (XII) 10 7
2,3-Di-Cl-naphthoquinone (XIII) 13 11
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itory power of the unsubstituted quinones. The mechanism of
inhibition remains unknown. As far as we know enzyme in-
hibition by these compounds has only been found for bacte-
rial collagenases which are strongly and irreversibly inacti-
vated by o-chloranil but rather weakly by p-chloranil. This
inactivation was found to be due to reaction with a tyrosyl
residue at the active site [26].
Irreversibility and strong inhibition are important prerequi-
sites for potential application as drugs against ureolytic bac-
teria. Many quinones, however, have been shown to be cyto-
toxic. Two general mechanisms have been elucidated:
oxidative stress following generation of reactive oxygen spe-
cies due to enzymatic redox cycling and loss of protein thiols
due to sulfhydryl arylation [27,28]. But the tyrosine modi¢ca-
tion mentioned above shows that more possibilities of inter-
action seem to exist.
Unsubstituted p-benzoquinone is highly toxic with an
LD50 value (lethal dose 50% kill) of 25^100 mg kg31 for
mice (http://www.cdc.gov/niosh/rtecs/dk280de8.html), p-naph-
thoquinone a little less (140^400 mg kg31 ; http://ntp-
support.niehs.nih.gov/NTP_Reports/NTP_Chem_HS_HTML/
NTP_Chem1/Radian130-15-4.html). Values for halogenated
compounds are scarce, but suggest a signi¢cantly reduced tox-
icity. For p-chloranil an LD50 of 4 g kg31 rat is reported
(http://www.cdc.gov/niosh/rtecs/dk682428.html). Lower con-
centrations, however, might be cancerogenic. In any case,
none of the halogenated compounds used in this study is
marked ‘toxic’ by the manufacturer as are benzo- and naph-
thoquinone. Most of them are classi¢ed as ‘irritant’.
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